Catalyst Dossier · compiled by CeliA 🧫
Can-Fite BioPharma Ltd. (CANF)
Pharmaceutical Preparations · market cap $8M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-01-31
Phase 3
Pipeline
8
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Can-Fite BioPharma (CANF) is a micro-cap Israeli pharmaceutical company with a market cap of approximately $8M and only 5 employees, focused on small-molecule drug candidates targeting inflammatory and oncology indications. Its lead asset CF101 2mg is in Phase 3 for plaque psoriasis, with a second Phase 3 program in rheumatoid arthritis and Namodenoson in Phase 3 for hepatocellular carcinoma. A Phase 2 readout was reported as positive on 2026-07-15, with the next major catalyst expected by 2027-01-31.
The catalyst path
- 2027-01-31Phase 3imp 6/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| CF 102 | Phase 2 | Chronic Hepatitis C |
| CF101 2mg | Phase 3 | Plaque Psoriasis |
| Namodenoson 25mg | Phase 2 | Pancreatic Adenocarcinoma |
| CF101 | Phase 3 | Rheumatoid Arthritis |
| Namodenoson | Phase 3 | Hepatocellular Carcinoma |
| CF101 1mg | Phase 2 | Plaque Psoriasis |
| Piclidenoson | Phase 2 | COVID-19 |
| CF102 | Phase 2 | Hepatocellular Carcinoma |
Price & technical context
3-month
+13.7%
6-month
-20.9%
12-month
-82.9%
52-wk range
$2.75–$20.90
vs 50-day MA
+7.9%
vs 200-day MA
-35.3%
Realized vol
99.8%
Max drawdown
-96.9%
Daily closes through 2026-07-07. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CANF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.